🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "huge turning point" in the effort against increasingly resistant strains of the bacteria, according to scientists.

A Worldwide Public Health Issue

Cases of gonorrhoea are on the rise around the world, with figures suggesting more than 82 million infections per year. Notably increased rates are seen in Africa and countries within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. Within England, cases have reached a record high, while rates across Europe in 2023 were three times higher compared to those in 2014.

“The authorization of new treatments for gonorrhoea is an significant and necessary development in the reality of increasing worldwide cases, increasing antimicrobial resistance and the extremely scarce therapeutic options at this time.”

Public health authorities are particularly alarmed about the surge in drug-resistant strains. The World Health Organization has designated it as a "priority pathogen". Recent surveillance revealed that resistance to standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Treatment Options Secure Approval

One new antibiotic, marketed under the name a brand name, was cleared by the US Food and Drug Administration in recent days for treating gonorrhoea. This STI can lead to major issues, including infertility. Researchers believe that focused deployment of this new drug will help slow the spread of drug resistance.

Gepotidacin, created by the pharmaceutical company GSK, also received approval in concurrent days. This treatment, which is also used to treat UTIs, was demonstrated in studies to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Partnership

This new treatment was the result of a innovative non-profit model for antibiotic development. The charitable organization GARDP collaborated with the pharmaceutical company its industry partner to develop it.

“This approval signifies a significant shift in the treatment of highly resistant gonorrhoea, which until now has been evolving faster than antibiotic development.”

Research Study Outcomes and Worldwide Availability

According to findings released by a major medical journal, the new drug successfully treated the vast majority of genital gonorrhoea infections. This places it at an comparable level with the current standard treatment, which combines an injection and a pill. The research included nearly 1,000 volunteers from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, the non-profit has the authority to license and sell the drug in many regions with limited resources.

Clinicians treating patients have shared optimism. Access to a one-pill regimen like this is hailed as a "revolutionary step" for managing the epidemic. This is considered vital to alleviate the strain of the illness for patients and to prevent the spread of extremely resistant gonorrhoea worldwide.